Spots Global Cancer Trial Database for Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Official Title: A Pilot Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer

Study ID: NCT06203821

Conditions

Pancreatic Cancer

Interventions

NP137

Study Description

Brief Summary: The objective of this study is to investigate whether adding the study drug, NP137, to a patient's treatment regimen (before surgery and in combination with chemotherapy afterward) can alter the behavior of pancreatic cancer..

Detailed Description: The aim of this study is to evaluate the mechanism of action for a novel anti-Netrin-1 antibody (NP137) in patients with pancreatic ductal adenocarcinoma. Pre-clinical data indicates that anti-Netrin-1 therapy can prevent/delay metastatic progression of disease by inducing cancer cell death through its dependence receptor Unc5b as well as prevent epithelial to mesenchymal transition (EMT). This pilot study is designed to provide vital translational scientific information that will inform the design of future clinical trials for NP137. This information includes determining the optimal use of NP137 with cytotoxic, as well as the treatment setting of resectable pancreatic cancer.